Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 30Gastrointestinal 10Thoracic 7Tumor-Agnostic 5Head & Neck 4Dermatologic 4Endocrine 3CNS 3Sarcoma 2Other solid neoplasm 2Gynecologic 2Other hematologic neoplasm 1NET 1Myeloid 1Lymphoid 1Breast 1

Conditions

Melanoma 4Uveal Melanoma 1Skin Neoplasms 1

Interventions

Ipilimumab 101pembrolizumab 94Nivolumab 87Cyclophosphamide 69fludarabine phosphate 55aldesleukin 52Interleukin-2 39Dacarbazine 35Vemurafenib 31fludarabine 30trametinib 29dabrafenib 29Temozolomide 28Whole-Body Irradiation 21Aminolevulinic Acid 21Carboplatin 20CTLA-4 Antigen 20Bevacizumab 20Radiotherapy 19Peripheral Blood Stem Cell Transplantation 19Radiosurgery 18Tacrolimus 17Mycophenolic Acid 17Paclitaxel 16HhAntag691 163-ingenyl angelate 16Busulfan 15Introns 14Antilymphocyte Serum 14encorafenib 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Axitinib × Dermatologic × Clear all
NCT01321437 2021-01-20

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

University of California, Irvine

Phase 2 Completed
11 enrolled 12 charts
Dermatologic

Melanoma

NCT01174238 2018-06-08

A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma

University of California, San Francisco

Phase 2 Completed
40 enrolled 10 charts
Dermatologic

Melanoma

NCT01533948 2018-05-09

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

Roswell Park Cancer Institute

Phase 2 Terminated
25 enrolled 11 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT00094107 2012-06-26

Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma

Pfizer

Phase 2 Completed
32 enrolled 9 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡